A Two-Biomarker Signal for Alzheimer’s Disease - Takeaways - MDSpire

A Two-Biomarker Signal for Alzheimer’s Disease

Dual plasma biomarkers may improve identification of established Alzheimer’s disease and signal faster decline

  • By

  • Henry Thomas

  • March 30, 2026

  • 3 min

Share

  • 1

    A combination of eMTBR-tau243 and plasma p-tau217 improves identification of established Alzheimer's disease.

  • 2

    The study involved 572 patients with cognitive symptoms, assessed through clinical evaluation and biomarker testing.

  • 3

    The two-biomarker approach showed 81% accuracy and 84% positive predictive value for established Alzheimer's disease.

  • 4

    Higher eMTBR-tau243 levels correlated with greater tau accumulation and faster cognitive decline over time.

  • 5

    The findings support a two-step testing strategy to differentiate asymptomatic amyloid pathology from significant Alzheimer's disease.

Original Source(s)

A Two-Biomarker Signal for Alzheimer’s Disease

  • by Henry Thomas

  • March 30, 2026

Related Content

SGLT2 Inhibitors Linked to Lower Epilepsy Risk

Real-world cohort data show lower epilepsy risk vs DPP-4 inhibitors in older patients with type 2 diabetes

Midlife Vitamin D Linked to Lower Tau

Higher vitamin D levels in early midlife were tied to lower tau burden on later brain imaging, while no association was seen with amyloid.

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.